δ in Dementia Clinical Trials

Inclusion Criteria: 1. Ambulatory outpatient volunteers with competent informants. Competent informants are cognitively normal individual(s) who interacts with the person on a regular (at least 5 or more hours/week) basis and in the opinion of the PI can provide adequate collateral information on the participant's memory and cognitive status. 2. Aged 65-100 years 3. Clinical diagnosis of AD, or MCI. 4. Capacity to give informed consent. If a patient is found to clinically decline during the course of the study and no longer able to provide consent, continued participation will be evaluated by the PI on a case-by-case basis. 5. GDS score (15 item) ≤ 8 6. No significant visual or hearing impairments 7. A standardized dECog score between 1.5 and 3.5 relative to ADNI's cohort. Exclusion Criteria: 1. A history of psychosis, including visual hallucinations; 2. History or treatment for Parkinson's, or tremor, or Rapid Eye Movement (REM) behavior disorder; 3. Treatment for cancer in the last 5 years (excluding skin cancers); 4. Major surgery in the last year; 5. Treatment for a seizure disorder with anticonvulsants 6. Current treatment with donepezil or any other AChEI or exposure within the last year. 7. Treatment with opiates, muscle relaxants, or systemic steroids. 8. In the opinion of the PI, treatment with AChEI is not appropriate due to a possible negative risk/benefit ratio based on past medical history or endorsement of symptoms during the screening interview. 9. In the opinion of the treating physician, the patient must begin therapy with AChEI immediately due to any delays having an unacceptable impact on the patient's QoL. 10. Co-participation in another study that the PI feels would pose a safety risk or adversely affect data integrity of this study.